Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide

Loredana Santo, Teru Hideshima, Diana Cirstea, Madhavi Bandi, Erik A. Nelson, Gullu Gorgun, Scott Rodig, Sonia Vallet, Samantha Pozzi, Kishan Patel, Christine Unitt, Matt Squires, Yiguo Hu, Dharminder Chauhan, Anuj Mahindra, Nikhil C. Munshi, Kenneth C. Anderson, Noopur Raje*

*Korrespondierende:r Autor:in für diese Arbeit

Publikation: Beitrag in Fachzeitschrift (peer-reviewed)Artikel in Fachzeitschrift

64 Zitate (Scopus)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide“. Zusammen bilden sie einen einzigartigen Fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry